Cancer - Allinky Biopharma

ALLINKY Biopharma
Go to content

Molecular science to discover new therapeutic compounds


The human genome includes all the information required for us to be born, grow, live, create and achieve. This information is safely stored in genes, yet it is information that can be hacked, turning a gene into an oncogene that is responsible for the onset and progression of cancer. The most prevalent oncogene in the human genetics is “ras”.

The uncontrolled expression of ras is responsible for many types of advanced and metastatic cancers, in particular pancreatic, lung, blood and colorectal cancer. Advanced pancreatic cancer is incurable simply because 95% of the cases bear the mutated ras oncogene. At present, there are a few experimental drugs targeting ras and just two approvals targeting G12C-Kras. In fact, for a long time it was coined as ”undruggable” until researchers from UCSF demonstrated the feasibility of targeting this oncogene. Allinky is currently developing a first-in-class oral medicine against ras-driven cancer that hopefully will offer benefits to many patients around the world.
Back to content